Last week, the top two contenders for first peanut allergy immunotherapy to market—DBV...
- DBV and Aimmune poised to dominate peanut allergy market
- Comorbidities are a significant concern in people with Type 2 diabetes
- Vertex prepares to bolster pipeline portfolio
- Can Liquidia’s LIQ861 offer a more convenient and effective treprostinil option for PAH patients?
- Four Developers that Will Expand the Use of FLT3 Inhibitors in the AML Market
DBV and Aimmune poised to dominate peanut allergy market
Last week, the top two contenders for first peanut allergy immunotherapy to market—DBV Technologies and Aimmune Therapeutics—presented to investors at the J.P. Morgan (JPM) Healthcare Conference in San Francisco.
Deals this week: UroGen Pharmaceuticals, Pherecydes Pharma, Tiziana Life Sciences
UroGen Pharmaceuticals Ltd has filed a registration statement with the US Securities and Exchange Commission (SEC) for a public offering of 1,135,847 shares at a price of $44.02 a unit to raise $50m.
M&As this week: Crescent Capital Partners, IPCA Laboratories Ltd
Crescent Capital Partners has acquired Nucleus Network Ltd from Baker IDI Heart and Diabetes Institute.
Comorbidities are a significant concern in people with Type 2 diabetes
Type 2 diabetes (T2D) is a chronic disorder of glucose equilibrium that results from the body’s inability to make use of available insulin along with relative insulin deficiency. Among adults only, T2D is expected to make up at least 95% of all diabetes cases.
Vertex prepares to bolster pipeline portfolio
Pavan Kottamasu, GlobalData Healthcare & Pharmaceutical Analyst Jeffrey Leiden, M.D., Ph.D., Chairman, President, and CEO of Vertex Pharmaceuticals, took the stage on Day 1 of the 2018 J.P. Morgan (JPM) Healthcare Conference at the Westin St. Francis in San Francisco, California, US, to present Vertex Pharmaceuticals’ key achieved milestones of 2017 and proposed goals for 2018.
M&As this week: Zymergen, Celgene Corp, China Biology Services Group Limited
Molecular technology firm Zymergen Inc has acquired Radiant Genomics Inc, a functional metagenomics research company.
Deals this week: AmpliPhi Biosciences, Argos Therapeutics, Juvenescence Limited
AmpliPhi Biosciences Corp plans to issue shares of its common stock in a public offering.
Can Liquidia’s LIQ861 offer a more convenient and effective treprostinil option for PAH patients?
On January 3, 2018, Liquidia Technologies announced the initiation of a Phase III clinical trial evaluating LIQ861 (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH).
Duaklir Genuair for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Duaklir Genuair (aclidinium bromide / formoterol fumarate) is an inhalation powder indicated as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.